An article by our collaborator Irene Tarragó

“Epilepsy walk with us every day and, for the biggest majority, always.”

Today coincide that the day I’m writing this article to the blog, is the International Day of Epilepsy. When you read it, the date will have passed, but check the number of records that have been programmed for this week (some also from this house). Paradoxically, most of the acts are by the initiative of somebody from the private sector: an ONG, an association, a company… But from the institutional sphere there is nothing. An awareness campaign would not be bad, indicating what to do in case of having a seizure or clarifying that people with epilepsy are not violent. Well, from my modest side, I will continue to insist that from some administrations it’s involved and there is something in favour of the investigation on epilepsy and their knowledge to be part of the society.

I will continue to insist that from some administrations it’s involved and there is something in favour of the investigation on epilepsy and their knowledge to be part of the society.

What we people who have epilepsy do know is that it does not happen in a day: epilepsy walk with us every day and, for the biggest majority, always.

“Always ahead!”

As I commented that I’m part of the group of privileged people who control her illness with drugs and scrupulously follow the rules, but every time, I think companies like mjn-neuro that investigate and seek to improve the quality of life of the patients with epilepsy, our life will be better. This wonderful father who left everything to seek a better life for his daughter and this girl who knew how to decide that she had to live with these letters. That’s the spirit. Always ahead!

And a lot of encouragement and I hope and say that you continue investigation in that field and in other diseases, to provide people with a life that is as comfortable as possible.

Leave a Reply

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.